ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Georgia » Pulmonary Disease

Top Pulmonary Disease Prescribers in Georgia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
THOMAS MURRAY M.D.

Pulmonary Disease

14,672

$760K

679
590 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 59%

$52
Average prescription price

Avg: $173

MASOOD AHMED M. D.

Pulmonary Disease

11,644

$792K

486
412 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

16%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 59%

$68
Average prescription price

Avg: $173

SUBRAHMANYA BHAT MD

Pulmonary Disease

10,669

$498K

439
223 are 65+

17%
patients receiving schedule two controlled substances

Avg: 1%

36%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 59%

$47
Average prescription price

Avg: $173

SHANKAR KANDASWAMY M.D.

Pulmonary Disease

9,387

$599K

570
420 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 59%

$64
Average prescription price

Avg: $173

VIJAY PATEL M.D.

Pulmonary Disease

8,369

$588K

559
428 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 59%

$70
Average prescription price

Avg: $173

JAMES MEADOWS MD

Pulmonary Disease

8,148

$570K

470
393 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 59%

$70
Average prescription price

Avg: $173

STUART SIMON M.D.

Pulmonary Disease

8,015

$1.16M

1185
849 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 59%

$144
Average prescription price

Avg: $173

ANDREW CICHELLI MD

Pulmonary Disease

7,838

$1.36M

792
558 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 59%

$173
Average prescription price

Avg: $173

JOHN KING M.D.

Pulmonary Disease

7,551

$642K

483
405 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 59%

$85
Average prescription price

Avg: $173

SIVARAMA MEDURI MD

Pulmonary Disease

5,848

$383K

149
70 are 65+

33%
patients receiving schedule two controlled substances

Avg: 1%

36%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 59%

$66
Average prescription price

Avg: $173

ANTHONY COSTRINI

Pulmonary Disease

5,810

$813K

427
341 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 59%

$140
Average prescription price

Avg: $173

TARSEM GUPTA MD

Pulmonary Disease

5,166

$526K

511
378 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 59%

$102
Average prescription price

Avg: $173

MANEL NAYAK M.D.

Pulmonary Disease

4,233

$659K

526
382 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 59%

$156
Average prescription price

Avg: $173

COLEMAN SUDDUTH M.D.

Pulmonary Disease

4,047

$717K

364
268 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 59%

$177
Average prescription price

Avg: $173

JEFFREY REID M.D.

Pulmonary Disease

3,963

$522K

478
336 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 59%

$132
Average prescription price

Avg: $173

ERICK KIMMERLING D.O.

Pulmonary Disease

3,773

$909K

441
351 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

86%
prescriptions for brand name drugs

Avg: 59%

$241
Average prescription price

Avg: $173

GIFFORD LORENZ M.D.

Pulmonary Disease

3,576

$421K

348
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 59%

$118
Average prescription price

Avg: $173

MOHAMMAD AL-MULKI M.D.

Pulmonary Disease

3,571

$224K

232
172 are 65+

10%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 59%

$63
Average prescription price

Avg: $173

GEORGE KANES M.D.

Pulmonary Disease

3,487

$234K

185
138 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 59%

$67
Average prescription price

Avg: $173

FRANCIS JENKINS MD

Pulmonary Disease

3,460

$316K

350
266 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 59%

$91
Average prescription price

Avg: $173

CRAIG WOLFF

Pulmonary Disease

3,400

$463K

446
323 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

55%
prescriptions for brand name drugs

Avg: 59%

$136
Average prescription price

Avg: $173

DANIEL CALLAHAN M.D.

Pulmonary Disease

3,324

$596K

465
411 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 59%

$179
Average prescription price

Avg: $173

DARSHAK PANDYA DO

Pulmonary Disease

3,244

$706K

397
275 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 59%

$218
Average prescription price

Avg: $173

STEPHEN CHITTY MD

Pulmonary Disease

3,223

$521K

361
263 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 59%

$162
Average prescription price

Avg: $173

FRANK DEMARCO MD

Pulmonary Disease

3,174

$660K

470
385 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 59%

$208
Average prescription price

Avg: $173

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank